Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

SGYP 4.59 -0.03 (-0.54%)
price chart
Synergy Pharmaceuticals: Don't Be An April Fool (SGYP)
Synergy Pharmaceuticals is up 59.31% since the publication of my article. Have you taken profits off the table? I have. And I'll tell you why.
Healthcare Stock's Buzzers - Synergy Pharmaceuticals (SGYP), OHR ...  Techsonian (press release)
Why Synergy Pharmaceuticals, Inc. Is Surging Higher Today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Synergy Pharma exploring sale: Bloomberg  Reuters UK
Four Gainers in the Spotlight: Akorn, Inc. (NASDAQ:AKRX), Synergy ...
On Friday, Following Stocks were among the �Top 100 Gainers� of U.S. Stock Market: Akorn, Inc. (NASDAQ:AKRX), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Harris Corporation (NYSE:HRS), Celldex Therapeutics, Inc. (NASDAQ:CLDX). Akorn, Inc.
Cantor Reiterates Buy on Synergy Pharmaceuticals Inc Following 4Q:14 Update
Cantor analyst Irina Rivkind came out with a research note on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after the company released its fourth-quarter results, posting a net loss of $30.6M and loss per share of ($0.32), coming in below the FactSet ...
Synergy Pharma (SGYP) Said To Be Exploring Sale Options
Apparently, Synergy began exploring options for a sale after Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), one of its competitors in the gastrointestinal drugs market, agreed to be acquired by Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) this month in a ...
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals, Inc. Short Interest Disclosure
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) encountered a rise of 2.6% or 355,379 shares in the short positions. The number escalated from 13,847,097 on February 13,2015 to 14,202,476 on February 27,2015.
First Call Rating Update on Synergy Pharmaceuticals, Inc.  Ashburn Daily
Morning Hot Watch List: Synergy Pharmaceuticals, Inc. (SGYP), Chevron ...  WallStreet Scope
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc (SGYP) Jumps 7.72% on March 26
Synergy Pharmaceuticals Inc ($SGYP) was among the biggest gainers on the Russell 2000 for Thursday March 26 as the stock popped 7.72% to $4.12, representing a gain of $0.295 per share.
Green-Zone Stocks to Track - Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ...
On Friday, Following stocks ended their trade in �Green-Zone�: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Juno Therapeutics Inc. (NASDAQ:JUNO), Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI), UBS Group AG (NYSE:UBS).